FierceBiotech3h
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
FierceBiotech4h
Inhibikase hits pause on Parkinson’s program over efficacy as it prioritizes lung drug
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
FierceBiotech18h
2 hormone therapies restore normal sleep in mouse models of amyotrophic lateral sclerosis
Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...
FierceBiotech18h
Fewer than 1% of clinical trials in the US include pregnant patients, study finds
Pregnancy comes with unique health risks and considerations, but pregnant people also continue to experience the same health ...
FierceBiotech21h
Stryker to spin off spinal implant business, as Viscogliosi Brothers-owned VB Spine
Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...
FierceBiotech22h
Zimmer Biomet nets foot-and-ankle specialist Paragon 28 for $1.1B
Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business, with a $1.1 billion deal to acquire the ...
FierceBiotech3h
Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...